133 results
8-K
ADAP
Adaptimmune Therapeutics Plc
11 Jun 24
Departure of Directors or Certain Officers
4:15pm
of healthcare benefits for a period of 12 months following such termination (formerly, nine months under the 2017 Executive Severance Policy). Our … salary for 12 months and to payment of premiums for continuation of healthcare benefits for a period of 12 months following such termination (no change
8-K
EX-10.1
ADAP
Adaptimmune Therapeutics Plc
11 Jun 24
Departure of Directors or Certain Officers
4:15pm
to receive severance benefits following termination of employment under certain conditions. The purpose of the Policy is to attract and retain qualified … .
(i)Accrued Benefits. Unless stated otherwise, where terms of this Policy are inconsistent to the terms of Executive’s Employment Agreement
8-K
bmxz94zk71vev01
27 Feb 24
Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company’s Sarcoma Franchise
8:13am
8-K
EX-10.1
025txqofamgp6pzvu2
27 Feb 24
Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company’s Sarcoma Franchise
8:13am
8-K
EX-10.1
io7vfday6u7x
29 Jun 23
Departure of Directors or Certain Officers
4:25pm
8-K
EX-10.2
va1 kout1
29 Jun 23
Departure of Directors or Certain Officers
4:25pm
8-K
EX-10.4
362u6 eno
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
8-K
EX-99.1
skd3ivb 2m
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
8-K
EX-10.3
mz289b
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
8-K
EX-10.2
auyt5zs619k17
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
8-K
EX-10.1
0axmc
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
425
5raloz3ln feim
30 May 23
Business combination disclosure
4:21pm
8-K
ikzfmefx86nob meyuqx
30 May 23
Submission of Matters to a Vote of Security Holders
4:18pm